YIDU TECH (02158) has repurchased 8 times since December, spending a total of approximately HK$14 million.

On December 16th, YIDU TECH (02158) announced that it repurchased approximately 640,000 shares at a price of HK$4.94 per share, with a total repurchase amount of about HK$3.2 million. Since December, the company has repurchased 8 times, totaling approximately 2.75 million shares and about HK$14 million. Behind the intensive repurchases is the firm recognition of the company's own value, supported by the improvement in performance and business expansion. In the mid-2026 fiscal year, YIDU TECH achieved key breakthroughs in profit quality and operational efficiency, with adjusted EBITDA of approximately HK$54 million, double that of the same period last year, almost achieving breakeven on the accounting level. EB SECURITIES pointed out in the tracking research report that the company has made significant progress in recent developments in AI medical innovation, including deep involvement in the National Artificial Intelligence Application Pilot Base in Beijing's medical field, winning Phase III clinical research projects, and adding "Hui Min Bao" business in Hebei and Guangzhou. The report believes that its medical big model has initially built a "data-algorithm-scenario" closed loop, driving the continuous implementation of business in multiple scenarios. It is also worth noting that Ms. Gong Rujing, the company's founder and chairman, was recently appointed as a member of the Advisory Committee of the Digital Medicine Research Institute at City University of Hong Kong, serving as a key bridge role connecting industry practice and academic research, promoting the integration of industry, academia, and research to a higher and more substantive level, and injecting new energy into the construction of the industry innovation ecosystem.